Post-earnings recap
Reported
Wed, May 6, 2026
EPS actual
$1.04
EPS est.
$0.87
EPS surprise
+18.71%
1-day move
+1.98%
Novo Nordisk's earnings report shows a significant beat on EPS, which likely contributed to the stock's 1.98% increase. However, the lack of revenue data and guidance leaves some uncertainty about future performance. Investors may be cautiously optimistic based on the EPS surprise, but without further details, the outlook remains unclear.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.04 | $6.96 | +18.71% |
| Revenue | — | $72.0B | — |
No transcript is on record for the earnings call, so the analysis is based solely on numerical results.
Novo Nordisk A/S is a global leader in diabetes care and hormone replacement therapies, operating in the Health Care sector. With a market cap of $197 billion, the company plays a crucial role in addressing chronic health issues, particularly diabetes, which affects millions worldwide.
Last quarter
In Q3-2025, Novo Nordisk reported an EPS of $0.69, falling short of the expected $0.77. The stock reacted positively the following day, gaining 0.44%.
EPS beat streak
2Q
EPS beat rate
63%
Avg EPS surprise
+39.05%
Avg 1-day reaction
-0.99%
Analysts are cautiously optimistic about Novo Nordisk's upcoming earnings, expecting a solid performance but with some concerns due to recent misses.
Bull case
If Novo Nordisk beats EPS estimates, it could signal strong demand for its diabetes products, leading to a positive stock reaction.
Bear case
A miss on EPS or revenue could raise concerns about market competition and pricing pressures, potentially leading to a negative stock reaction.
Key metrics to watch
EPS
$6.96Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating income.
Revenue
$72.0BTotal revenue reflects the company's sales performance and market demand for its products, which is critical for assessing growth.
The print will turn on these.
Q1
Will the EPS exceed the consensus estimate of $6.96?
A beat on EPS could indicate strong operational performance and boost investor confidence.
Q2
What is the outlook for revenue growth compared to the consensus of $72.0B?
Revenue growth is crucial for assessing the company's market position and future prospects.
—
Est. EPS
$0.01
Est. Rev
$918M
Impl. Move
±9.1%
Why consensus could be wrong
The consensus may underestimate the potential for Novo Nordisk to exceed revenue expectations due to strong demand for its diabetes products.
Supporting evidence
Recent historical performance shows a 63% EPS beat rate, indicating potential for positive surprises.
Options pricing suggests a larger move than historical averages, indicating heightened expectations.
Key risk
If revenue growth significantly outpaces the $72.0B consensus, it could shift market sentiment positively.
Pre-commit to what would confirm each case.
This quarter's results will be closely watched as they reflect the company's ability to navigate a competitive pharmaceutical landscape.
Bull confirmed if
An EPS of $7.50 or higher would confirm strong demand and operational efficiency.
Bear confirmed if
An EPS below $6.00 would raise concerns about profitability and market competitiveness.
What the market is pricing for the move.
Implied Move
±11.3%
Historical Avg
±3.2%
The options market is pricing in a significant move, suggesting traders expect volatility around the earnings announcement.
Options are pricing ±11.3% while NVO has averaged ±3.2% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
33.0%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options rich in Health Care
Fade rate: 4 of 18 (22%)
This setup has occurred 30 times across Health Care in the last 2 years. 14 of 18 (78%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.8%, with a raw directional average of +3.0% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
9.89%
of float
Insider
0.00%
of float
Holders
1,605
institutions
Top Holders· as of Jun 2026
Dodge & Cox Inc.
20,397,110 sh · $780.4M
0.60%
5.5%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Novo Nordisk beats expectations, history suggests the stock could rise by about 0.22%, confirming positive market sentiment.
In line / cautious
If results are in line but management's commentary is cautious, the stock may see little movement as investors digest the information.
Miss
A miss on earnings could lead to a decline of around 4.09%, reflecting investor disappointment and concerns about future performance.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
3
1 buy·2 sells
Members
2
House only
Est. Notional
$3,003.00–$45,000.00
disclosed dollar ranges
Most Active Members
2 trades
The lines on the call that would change the story.
LOOMIS SAYLES & CO L P
18,594,352 sh · $711.4M
0.55%
9.3%
Franklin Resources, Inc.
13,041,109 sh · $499.0M
0.38%
-18.9%
Price (T.Rowe) Associates Inc
11,704,719 sh · $447.8M
0.35%
5.8%
Morgan Stanley
11,659,869 sh · $446.1M
0.34%
7.3%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
1 trade
Net buying
Recent Transactions
Traded Sep 10, 2026 · disclosed Sep 25, 2026
$1,001.00–$15,000.00
Traded Aug 31, 2026 · disclosed Sep 25, 2026
$1,001.00–$15,000.00
Traded Aug 26, 2026 · disclosed Sep 17, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.